110 research outputs found
FĂ©loldali vese gyűjtĹ‘csatornás daganatának eredmĂ©nyes palliatĂv kemoterápiás kezelĂ©se anuria mellett
Absztrakt
A szerzők 54 éves nőbeteg esetét mutatják be. Kétoldali (Bellini-)
gyűjtőcsatornából kiinduló, multiplex tüdőmetasztázisokat adó vesetumor miatt
jobb oldali nephrectomia történt. Az ellenoldali vesében progrediáló daganat
akut komplett anuriás veseelĂ©gtelensĂ©get okozott. DialĂzist Ă©s palliatĂv
gemcitabin (1000 mg/m2)–cisplatin (70 mg/m2) kemoterápiát
kezdtek. A kezelés mellett a beteg vesefunkciója javult, a 6 ciklust kitevő
kemoterápiás vonal vĂ©geztĂ©vel a dialĂzist felfĂĽggesztettĂ©k. FĂ©l Ă©vvel kĂ©sĹ‘bb
uralhatatlan lokális és pulmonalis progresszió miatt a beteget elvesztették. A
potenciálisan nephrotoxicus cisplatin kemoterápia komplex szupportĂv kezelĂ©s
mellett a diffĂşzan infiltratĂv tumor kontrollja rĂ©vĂ©n a vesefunkciĂłt javĂtotta,
Ă©s aktĂv háztartási munkavĂ©gzĂ©s mellett a beteg egyĂ©ves tĂşlĂ©lĂ©sĂ©t tette
lehetővé. Orv. Hetil., 2016, 157(11), 436–439
miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice
Abstract Background: Micro RNAs are small, non-coding, single-stranded RNAs that negatively regulate gene expression at the post-transcriptional level. Since miR-143 was found to be down-regulated in prostate cancer cells, we wanted to analyze its expression in human prostate cancer, and test the ability of miR-43 to arrest prostate cancer cell growth in vitro and in vivo. Results: Expression of miR-143 was analyzed in human prostate cancers by quantitative PCR, and by in situ hybridization. miR-143 was introduced in cancer cells in vivo by electroporation. Bioinformatics analysis and luciferase-based assays were used to determine miR-143 targets. We show in this study that miR-143 levels are inversely correlated with advanced stages of prostate cancer. Rescue of miR-143 expression in cancer cells results in the arrest of cell proliferation and the abrogation of tumor growth in mice. Furthermore, we show that the effects of miR-143 are mediated, at least in part by the inhibition of extracellular signal-regulated kinase-5 (ERK5) activity. We show here that ERK5 is a miR-143 target in prostate cancer. Conclusions: miR-143 is as a new target for prostate cancer treatment
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population
Influence du choix du point d'acupuncture dans la prise en charge des nausées et vomissements induits par la chimiothérapie (à propos de 41 patientes traitées pour un cancer du sein au CRLC Val d'Aurelle)
MONTPELLIER-BU MĂ©decine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocMONTPELLIER-BU MĂ©decine (341722104) / SudocSudocFranceF
Intérêt des dosages sériques de l' ACE et du CA 15.3 dans les cancers du sein métastatiques traités par chimiothérapie cytotoxique (à propos de quatre-vingt seize patientes prises en charge au C.R.L.C. de Montpellier)
MONTPELLIER-BU MĂ©decine (341722104) / SudocMONTPELLIER-BU MĂ©decine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Traitement par interleukine-2 et interféron-alpha administrés par voie sous-cutanée dans le cancer du rein métastatique (résultats d'une expérience régionale chez 78 patients)
MONTPELLIER-BU MĂ©decine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocMONTPELLIER-BU MĂ©decine (341722104) / SudocSudocFranceF
Adénocarconome de la prostate métastatique à PSA < 10 ng/ml (expérience au Centre Val d'Aurelle)
MONTPELLIER-BU MĂ©decine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocMONTPELLIER-BU MĂ©decine (341722104) / SudocSudocFranceF
Facteurs pronostiques des tumeurs épithéliales de l'ovaire, traitées par chimiothérapie (apport des dosages sériques du CA 125)
MONTPELLIER-BU MĂ©decine (341722104) / SudocMONTPELLIER-BU MĂ©decine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
- …